Samir Parekh, M.D.

parekh11

Albert Einstein College of Medicine
Targeting NOXA methylation to overcome Bortezomib resistance in MCL

Mantle cell lymphoma is an aggressive type of non-Hodgkin’s lymphoma characterized by frequent relapses and usually fatal in the majority of patients. We are trying to understand precisely why patients do not respond to Bortezomib, a standard chemotherapy for this disease using cutting-edge next generation sequencing tools. We will then find ways to make cancer cells more sensitive to Bortezomib by switching on our body’s internal cell death mechanisms. Our studies are aimed at ultimately developing clinical trials that will overcome Bortezomib resistance in MCL patients.